(Press-News.org) Black patients with early-stage liver cancer appear more likely to die of the disease than Hispanic or white patients with the same condition, according to a report in the December issue of Archives of Surgery, one of the JAMA/Archives journals.
Hepatocellular carcinoma, or cancer of the liver, is the fifth leading cause of cancer death worldwide, according to background information in the article. The five-year rate of survival for patients with advanced-stage disease is 5 percent, but those who are diagnosed at an early stage are more likely to be successfully treated. "The available treatment strategies, including tumor ablation, hepatic resection, liver transplant or combined modalities, require highly complex care only available in tertiary referral centers," the authors write. "To obtain care in these centers, patients need to overcome several barriers that may precipitate health care disparities along racial/ethnic lines and may have downstream effects on survival."
Amit K. Mathur, M.D., M.S., and colleagues at the University of Michigan, Ann Arbor, analyzed data from the National Cancer Institute's Surveillance, Epidemiology and End Results (SEER) registry. They identified a total of 13,244 patients who were diagnosed with stage I or II hepatocellular carcinoma between 1995 and 2006.
Of the patients, 6,316 (47.7 percent) were white, 3,022 (22.8 percent) were Asian, 2,230 (16.8 percent) were Hispanic, 1,397 (10.5 percent) were black and 279 (2.1 percent) were categorized as other. During the study period, a total of 32.8 percent of all patients received invasive therapy for liver cancer. Black and Hispanic patients were less likely to receive such treatments than white, Asian or other patients.
Five-year survival rates were 17.9 percent for all patients, 18.2 percent for white patients, 12.2 percent for black patients, 15.2 percent for Hispanic patients, 22 percent for Asian patients and 17.1 percent for other patients. Median (midpoint) survival times were 15 months for Asians, 10 months for whites and Hispanics and eight months for blacks.
After adjusting for the type of treatment received, black patients had a 12 percent increased rate of death when compared with white patients, Hispanic and white patients had similar rates of death and Asian patients had a 16 percent lower death rate.
"The most notable finding in our study was that racial/ethnic variation in hepatocellular carcinoma outcome is related to access and variable treatment effect from specific therapies," the authors write. "After adjusting for treatment effects, the racial/ethnic disparity in survival between black and white patients decreased but persisted. This finding is linked to two major issues that contribute to health-related disparities in minority populations: black patients have poor access to treatment, and, even after obtaining treatment, they have relatively poor outcomes compared with white patients."
The results have important implications for health policy, they note. "Some evidence suggests that racial/ethnic disparities in access to specialized care may be linked to the providers and facilities that serve minority patients. Further provider education on the importance of hepatocellular carcinoma screening in at-risk groups may be helpful in alleviating these disparities," the authors conclude. "Persistent racial/ethnic disparities in survival even after adjusting for the effects of treatment are of particular concern and may be related to the quality of health care delivered. This variation may require a comprehensive evaluation of centers where minorities receive care to standardize and improve the structure and process of cancer care delivery."
INFORMATION:
(Arch Surg. 2010;145[12]:1158-1163. Available pre-embargo to the media at www.jamamedia.org.)
Editor's Note: This study was supported in part by a T32 training grant in surgical oncology from the National institutes of Health. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
To contact corresponding author Christopher J. Sonnenday, M.D., M.H.S., call Nicole Fawcett at 734-764-2220 or e-mail nfawcett@med.umich.edu.
For more information, contact JAMA/Archives Media Relations at 312/464-JAMA (5262) or e-mail mediarelations@jama-archives.org.
Racial disparities evident in early-stage liver cancer survival
2010-12-21
ELSE PRESS RELEASES FROM THIS DATE:
Features of the metabolic syndrome common in persons with psoriasis
2010-12-21
Individuals with psoriasis have a high prevalence of the metabolic syndrome, according to a report posted online today that will appear in the April 2011 print issue of Archives of Dermatology, one of the JAMA/Archives journals.
According to background information in the article, individual features of the metabolic syndrome include obesity, high blood pressure, diabetes and high total cholesterol and triglycerides. Additional background information notes that while past studies have suggested a link between psoriasis and individual components of the metabolic syndrome, ...
About one-fifth of women, less than 7 percent of men report use of indoor tanning
2010-12-21
Women are more likely to report use of indoor tanning facilities than men, and some characteristics common to indoor tanners differ by sex, according to a report in the December issue of Archives of Dermatology, one of the JAMA/Archives journals. However, few tanners—male or female—mention avoiding tanning beds when asked about ways to reduce skin cancer risk.
"Skin cancer is the most common form of malignancy in the United States. The American Cancer Society estimated that 1 million new cases of melanoma and non-melanoma skin cancer were diagnosed in 2009; 8,650 deaths ...
Most patients can speak and swallow after combination treatment for head and neck cancer
2010-12-21
Most patients do not have ongoing speaking or swallowing difficulties following combined chemotherapy and radiation treatment for advanced head or neck cancer, but several factors may be associated with worse outcomes in these functions, according to a report in the December issue of Archives of Otolaryngology–Head & Neck Surgery, one of the JAMA/Archives journals.
"Speaking and swallowing deficits are experienced by many survivors of primary cancers of the head and neck," the authors write as background information in the article. "Although it is often difficult to separate ...
Outcomes after recurrence of oral cancer vary by timing, site
2010-12-21
Patients who have recurrence of oral squamous cell carcinoma tend to do worse if the new cancer appears at the same site early or if it appears in the lymph nodes six months or longer after initial treatment, according to a report in the December issue of Archives of Otolaryngology–Head & Neck Surgery, one of the JAMA/Archives journals.
Treating recurrences of oral squamous cell carcinoma (cancer in the thin, flat cells that line the lips and mouth) involves balancing the risk of complications against the potential benefit to the patient in terms of survival or controlling ...
Study finds injectable and oral birth control do not adversely affect glucose and insulin levels
2010-12-21
GALVESTON, December 17, 2010 – Fasting glucose and insulin levels remain within normal range for women using injectable or oral contraception, with only slight increases among women using depot medroxyprogesterone acetate (DMPA), commonly known as the birth control shot, according to new research from the University of Texas Medical Branch (UTMB Health) in Galveston.
The study, published in the January 2011 issue of Obstetrics and Gynecology and conducted over three years, is the largest to measure fasting glucose and insulin levels among women using DMPA, oral (desogestrel) ...
Factors linked to speech/swallowing problems after treatment for head and neck cancers
2010-12-21
DURHAM, NC – Most patients with locally advanced head and neck cancers who successfully complete treatment with chemotherapy and radiation manage to do so without losing the ability to speak clearly and swallow comfortably, according to researchers at the Duke Cancer Institute.
"This is good news," said Joseph K. Salama, MD, an assistant professor of radiation oncology at Duke and the corresponding author of the study. "I hope it brings some comfort to newly-diagnosed patients who are understandably worried about what long-term effects treatment might involve."
The ...
New research shows virus previously linked to chronic fatigue syndrome is a lab contaminant
2010-12-21
A virus previously thought to be associated with chronic fatigue syndrome is not the cause of the disease, a detailed study has shown. The research shows that cell samples used in previous research were contaminated with the virus identified as XMRV and that XMRV is present in the mouse genome.
XMRV was first linked to chronic fatigue syndrome – also known as myalgic encephalomyelitis (ME) – in a study published in October 2009, where blood samples from chronic fatigue syndrome patients were found to have traces of the virus. XMRV had also been identified previously in ...
Without intervention, Mariana crow to become extinct in 75 years
2010-12-21
Researchers from the University of Washington say the Mariana crow, a forest crow living on Rota Island in the western Pacific Ocean, will go extinct in 75 years.
The extinction could happen almost twice as soon as previously believed.
The crow's extinction can be prevented with a bird management program that focuses on helping fledgling birds reach their first birthday, said James Ha, UW research associate professor in psychology.
Ha examined survival rates in 97 Mariana crows – Corvus kubaryi – that had been tracked between 1990 and 2010 by researchers. He found ...
Finnish researchers find a compound that prevents the growth of prostate cancer cells
2010-12-21
Evidence pointing to the effects of monensin emerged in a project investigating the effects of nearly 5,000 drugs and micromolecules on the growth of prostate cancer cells. The project involved most of the drugs on the market today. Researchers found that small amounts of compounds – disulfiram (Antabus), thiram, tricostatin A, and monensin – can prevent the growth of prostate cancer cells without significant effects on the growth of the normal human prostate epithelial cells.
Further studies revealed that monensin caused prostate cancer cell death by reducing the amount ...
Subsidies have no effect on Spanish cinema productivity
2010-12-21
Awards have an impact on Spanish movie productivity, since they increase internal and external distribution demand, but subsidies have no effect whatsoever on the productivity of the Spanish film industry. This is the conclusion of researchers at the University of Granada (UGR), who have studied the production of films in Spain.
"Awards increase the amount of films produced by increasing productivity. In other words film industry workers and companies are more productive and efficient. However, we did not detect that subsidies had any such effect on productivity", Henry ...